Ironwood Pharmaceuticals Inc (IRWD): Lawrence S Olanoff , director of Ironwood Pharmaceuticals Inc sold 2,200 shares on Jun 3, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $12.92 per share for a total value of $28,424.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 27, 2016, Halley E Gilbert (Chief Legal Officer) sold 20,275 shares at $12.19 per share price.On Mar 11, 2016, Peter M Hecht (Chief Executive Officer) sold 120,000 shares at $10.72 per share price.Also, On Mar 11, 2016, Mark G Currie (Chief Scientific Officer) sold 150,000 shares at $10.86 per share price.On Mar 9, 2016, Lawrence S Olanoff (director) sold 2,200 shares at $11.11 per share price.
Shares of Ironwood Pharmaceuticals (IRWD) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.26 points or -1.97% at $12.95 with 13,10,387 shares getting traded. Post opening the session at $13.15, the shares hit an intraday low of $12.72 and an intraday high of $13.18 and the price vacillated in this range throughout the day. The company has a market cap of $1,873 M and the number of outstanding shares has been calculated to be 14,46,04,310 shares. The 52-week high of Ironwood Pharmaceuticals is $14.2 and the 52-week low is $7.35.
Company has been under the radar of several Street Analysts.Ironwood Pharmaceuticals is Reiterated by Mizuho to Buy and the brokerage firm has raised the Price Target to $ 16 from a previous price target of $15 .The Rating was issued on May 10, 2016.Ironwood Pharmaceuticals is Reiterated by Wedbush to Neutral and the brokerage firm has raised the Price Target to $ 10 from a previous price target of $9 .The Rating was issued on Apr 28, 2016.Ironwood Pharmaceuticals is Initiated by Goldman to Neutral. The Rating was issued on Mar 21, 2016.
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.